How can ‘big’ data help drug candidates through the pipeline? And who does the data belong to? LSIPR spoke to NuMedii chief executive Gini Deshpande.
R&D in the pharmaceutical industry is having a tough time. As blockbuster drugs fall foul of the so-called ‘patent cliff ’, and the cost of healthcare continues to rise, many big pharma companies, including Merck, Novartis and AstraZeneca, have resorted to laying off R&D staff to cut costs.
Pushing pipeline drugs through to the approval stage as quickly as possible is as crucial as ever, but the business of bringing new therapies to market from discovery to bathroom cabinets is an expensive and risky endeavour.
While it’s difficult to calculate the full cost of bringing a new drug to market, Forbes estimates that given the low success rate of drug candidates making it to market (95 percent of candidates fail to show their safety and efficacy, it says) on average, pharmaceutical companies will spend about $5 billion on each successful medicine.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
NuMedii, big data, drug discovery, de-risking, IP strategy